The general transcription factor TFIIB plays a crucial role in the assembly of the transcriptional preinitiation complex and has also been proposed as a target of transcriptional activator proteins (reviewed in [1] 
Results and discussion
We tested several TFIIB derivatives containing single and double point mutations in the highly conserved amino-terminal domain for their ability to support transcriptional activation mediated by the VP16 activation domain in vivo ( Figure 1c ). The reporter construct G5E4CAT was transfected into human embryonic kidney 293 cells along with an expression vector encoding amino acids 1-93 of GAL4 fused to VP16 (GAL4-VP16), and either an empty cytomegalovirus (CMV) expression vector or the TFIIB derivatives indicated in Figure 1c under the control of the CMV promoter. All of the TFIIB derivatives were expressed at equivalent levels, as assessed by immunoblotting. Total RNA was extracted and the E4 transcripts detected by primer extension. As we observed with GAL4 activation region II (RII) [4] , TFIIB R66E but not TFIIB E51R inhibited transcriptional activation by GAL4-VP16. TFIIB R66A also inhibited transcriptional activation by GAL4-VP16, but not to the same degree as TFIIB R66E. TFIIB R66K did not significantly inhibit transcriptional activation by GAL4-VP16, however, confirming the importance of a charged residue at position 66. In addition, the inhibitory effect of TFIIB R66E was reversed by the second mutation E51R (E51R:R66E). Taken together Figure 1 (a) Schematic illustration of TFIIB. The bars at the top indicate the regions involved in both the intramolecular interaction and the interaction with VP16. The sequence of amino-acid residues 36-70 is shown below in the single-letter amino-acid code; highly conserved residues are shaded. The amino acids mutated in this study (bold) are indicated by arrows. N, amino terminus; C, carboxyl terminus. The two direct repeats of TFIIB are indicated by the shaded regions containing arrows and the plus signs indicate the charged residues of the basic amphipathic helix. with the previous studies in yeast and our experiments with the GAL4 RII activation domain, the data indicate that a salt bridge between TFIIB residues E51 and R66 is required for transcriptional activation in vivo [4, 6] .
The mutant E51R, unlike TFIIB R66E, did not inhibit transcriptional activation in vivo, suggesting that a more complex mechanism may be involved. We therefore tested whether the inhibitory effect of R66E could be reversed by the substitution of an acidic residue other than E51 with a basic residue. We substituted the highly conserved residue D47 (Figure 1a ) with lysine to produce a double point mutant D47K:R66E, and tested its effect on transcriptional activation by GAL4-VP16 in vivo. D47K reversed the inhibitory effect of R66E in a manner similar to that observed with E51R. Thus, the ability of TFIIB to support transcriptional activation in vivo is dependent on the interplay of at least three charged residues.
We next tested the ability of the TFIIB mutants to interact with 35 S-labelled GAL4-VP16 (Figure 2a ) in a farwestern assay identical to that previously used to monitor this interaction [2] . Equal amounts of recombinant wild-type TFIIB and the mutants E51R, R66E and E51R:R66E were resolved by SDS-PAGE, transferred to membrane and probed with 35 S-labelled GAL4-VP16 ( Figure 2b ). Binding was assessed by autoradiography (upper panel) and quantitation performed by phosphorimager analysis. The same membrane was then immunoblotted with a monoclonal antibody that recognises the T7 epitope tag at the carboxyl terminus of all the derivatives (lower panel). The relative affinities of wild-type TFIIB and the mutants for GAL4-VP16 are shown graphically in Figure 2b after normalisation against the signal quantified from the immunoblot. Compared with wild-type TFIIB, E51R showed a consistently small increase in its affinity for GAL4-VP16 (1.7-fold). Strikingly, TFIIB R66E was significantly impaired in its ability to interact with GAL4-VP16 (10-fold). The affinity of the double point mutant TFIIB E51R:R66E for GAL4-VP16 was similar to that of wildtype TFIIB, however. Thus, the human TFIIB mutant R66E is defective for interaction with an acidic activation domain, consistent with the defect in supporting transcriptional activation by acidic activators in vivo. Furthermore, the defect in the VP16 interaction is reversed in E51R:R66E, as is the transcription defect in vivo.
The RAP30 subunit of the transcription factor TFIIF has previously been shown to interact with TFIIB [7, 8] . We performed the same farwestern assay using 35 S-labelled RAP30 (Figure 2a) as the probe (Figure 2c ). The mutants E51R and E51R:R66E both showed a small increase in affinity for RAP30. Significantly, in contrast to the effect on interaction with GAL4-VP16, TFIIB R66E showed only a slight decrease in affinity for RAP30. In addition, all of the TFIIB mutants were able to associate with RNA polymerase II (Pol II) in an immunoprecipitation assay (Figure 2d ). We conclude that TFIIB R66E is severely and specifically compromised in its ability to interact with GAL4-VP16 and this effect is reversed in the double point mutant E51R:R66E.
The amino terminus of human TFIIB (including the region harbouring the above mutations) is dispensable for the interaction with GAL4-VP16 [2] . Indeed, deletion of The TFIIB mutant R66E is specifically defective in its interaction with GAL4-VP16. residues 4-85 of human TFIIB enhances the affinity for VP16 (Figure 3a ) [2] . This effect is due to the intramolecular interaction between the amino and carboxyl termini of TFIIB, which competes with the interaction between VP16 and the carboxy-terminal domain. We therefore considered the possibility that the defect in the interaction between the human TFIIB mutant R66E and VP16 was due to a modulation of the TFIIB intramolecular interaction. Protein affinity chromatography was used to monitor the interaction in trans between the TFIIB carboxy-terminal domain and an immobilized glutathione-S-transferase (GST) fusion protein of TFIIB residues 1-124 ( Figure 3b) . As seen previously, the carboxy-terminal domain of TFIIB stably interacted with the immobilised amino terminus [2] . The immobilised TFIIB amino terminus containing the mutation E51R also interacted with the carboxyl terminus. Significantly, the amino-terminal domain mutant R66E interacted with the carboxy-terminal domain with enhanced affinity and this effect was reversed in the double mutant E51R:R66E. Taken together with the farwestern data, we conclude that the human TFIIB mutant R66E exhibits a higher affinity in its intramolecular interaction and that this in turn reduces the affinity for VP16.
Our transfection experiments showed that the charge of TFIIB residue R66 was the critical requirement to support transcriptional activation by GAL4-VP16. Farwestern analysis showed that TFIIB R66A was defective in its ability to interact with GAL4-VP16, but not to the same extent as R66E (Figure 4a) . R66K, however, showed a 2.7-fold enhancement in affinity for GAL4-VP16 compared with wild-type TFIIB, suggesting a weakening of the intramolecular interaction. Thus, these data demonstrate that the charge of TFIIB residue 66 is critical in determining the ability of TFIIB to interact with VP16 and, hence, also the affinity of the intramolecular interaction. Moreover, the VP16 interaction defect was also reversed in the double mutant D47K:R66E. Significantly, these data parallel the ability of the TFIIB derivatives to support transcriptional activation in vivo. We therefore conclude that TFIIB residues D47, E51 and R66 coordinately regulate the affinity of the intramolecular interaction between the aminoand carboxy-terminal domains of TFIIB and that this regulates the response to transcriptional activators in vivo.
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Figure 3
The TFIIB mutations affect the interaction between the amino-and carboxy-terminal domains of TFIIB. (a) Farwestern analysis of a TFIIB mutant lacking amino-acid residues 4-85 (∆4-85). The probe was 35 S-labelled GAL4-VP16 as in Figure 2b. (b) The T7-tagged carboxyl terminus of TFIIB was incubated with agarose beads coupled to GST fusion proteins of the indicated amino-terminal TFIIB derivatives (1 µg) as described previously [2] . A gel stained with Coomassie blue is shown below. Bound TFIIB carboxy-terminal domain was detected by immunoblotting with anti-T7 monoclonal antibody. The first lane (I) shows 5% of the input TFIIB carboxyl terminus used in the assay. (a) TFIIB mutants that are defective in transcriptional activation in vivo also affect the interaction with GAL4-VP16. Farwestern analysis with 35 S-labelled GAL4-VP16 (as in Figure 2b ) using wild-type (WT) TFIIB or the indicated TFIIB derivatives. (b) Model depicting the mechanism by which TFIIB R66E inhibits transcriptional activation in vivo. In the presence of wild-type TFIIB (left), the activator recruits the holoenzyme by engaging contact with TFIIB. Holoenzymes containing TFIIB R66E (right) are not efficiently recruited to the promoter because the activator-TFIIB interaction is compromised by the increased affinity of the TFIIB intramolecular interaction.
Previous studies used biochemical assays to show that VP16 can disrupt the TFIIB intramolecular interaction [2] . Here, we have provided evidence that the TFIIB intramolecular interaction regulates transcriptional activation in vivo. A role for the amino terminus of TFIIB in transcriptional activation is not without precedent. A recent study described a mutant of yeast TFIIB (S53P) that is defective in supporting transcriptional activation by Pho4 even though the amino terminus of TFIIB is dispensable for the interaction [9] . In addition, a study by Knaus et al. [10] found that overexpression of a yeast protein similar to the mammalian coactivator PC4 (SUB1) was able to suppress the slow growth phenotype observed with the yeast TFIIB mutant R78H. A recent report using an R64E mutant of yeast TFIIB suggested that the intramolecular interaction enhances assembly of a TATA-binding protein (TBP)-TFIIB-promoter complex, although a comparable human mutant (R53E) was not as effective [11] . Consistent with this, we have found that human TFIIB R66E forms a TBP-TFIIB-promoter complex with a similar affinity to wild-type TFIIB (see Supplementary material).
The fact that TFIIB R66E inhibits transcriptional activation in vivo strongly suggests that it is engaging in interactions with components of the transcription machinery and preventing their utilisation in transcriptional activation. We have shown that TFIIB R66E is not significantly compromised in its ability to interact with either Pol II or TFIIF in vitro. Our data therefore support the idea that, in a living cell, TFIIB is complexed with the Pol II holoenzyme. We propose that the mutant R66E is able to displace wild-type TFIIB from the holoenzyme in vivo. Consequently, this would prevent activator-mediated recruitment of the holoenzyme through TFIIB contact (Figure 4b ). This model would be consistent with several previous observations. Firstly, recruitment of the holoenzyme has been reported to be a crucial function of transcriptional activation domains [12, 13] . Secondly, TFIIB is able to elicit transcriptional activation when linked to a DNA-binding domain in 'activator-bypass' experiments that function by holoenzyme recruitment [14] [15] [16] . Finally, overexpression of TFIIB mutants unable to interact with Pol II/TFIIF do not inhibit transcription in yeast, strongly suggesting that assembly of TFIIB into the holoenzyme is required for the recruitment of TFIIB to the promoter in vivo [15] .
It was originally speculated that the TFIIB intramolecular interaction might modulate the association of TFIIB with TFIIF and Pol II [2] . Our present work suggests that this is not the case. The data suggest that one function may be to modulate the response to activator proteins. This would be consistent with a previous report which showed that raising the concentration of a TFIIB-containing yeast holoenzyme in vitro can overcome the requirement for an activator at the adenovirus E4 promoter [12] . The content/conformational status of the holoenzyme may define the affinity of the TFIIB intramolecular interaction, and thus modulate access to TFIIB by a given activation domain. In summary, our results provide evidence that the conformational status of components of the transcription machinery plays a crucial role in the regulation of gene expression.
Supplementary material
Supplementary material including additional methodological detail and a figure showing that TFIIB derivatives form a TBP-TFIIB-promoter complex is available at http://current-biology.com/supmat/supmatin.htm.
